位置:首页 > 产品库 > Angiopeptin TFA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Angiopeptin TFA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Angiopeptin TFA图片
CAS NO:2478421-60-0
包装与价格:
包装价格(元)
5mg询价
10mg询价
25mg询价

Angiopeptin TFA 是生长抑素的环状八肽类似物,是一种 sst2/sst5 受体部分激动剂,IC50 值分别为 0.26 nM 和 6.92 nM。Angiopeptin TFA 可以抑制生长激素释放和胰岛素样生长因子-1 (IGF-1) 产生。Angiopeptin TFA 抑制腺苷酸环化酶或刺激细胞外酸化。Angiopeptin TFA 具有用于冠状动脉粥样硬化研究的潜力。
Cas No.2478421-60-0
别名血管抑肽三氟乙酸盐
分子式C58H73F6N11O14S2
分子量1326.39
溶解度Water : 10 mg/mL (7.54 mM; Need ultrasonic)
储存条件-20°C, away from moisture
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibit adenylate cyclase or stimulate extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research[1][2].

Angiopeptin (0.1 nM- 10 μM; for 1 h) TFA acts as a partial agonist (pEC50=6.57) with a maximum response of 423% at 3 μM on the release of tritium on CHO hsst2 cells[2].

Angiopeptin (20 and 50μg/kg; i.h.) TFA significantly inhibits neointimal formation[1].Angiopeptin (20 μg/kg; per day) TFA significantly inhibits coronary artery myointimal proliferation in cardiac allografts by appmximalely 50%[1].

[1]. Lundergan CF, et al. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J Am Coll Cardiol. 1991;17(6 Suppl B):132B-136B.
[2]. Alderton F, et al. Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides. Br J Pharmacol. 2001;132(3):760-766.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024